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Abstract
Background: Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT)
is currently treated with systemic corticosteroids despite poor efficacy and side effects. This study investigated the
therapeutic effect of budesonide/formoterol, montelukast and n-acetylcysteine, which are suggested as treatment
options for BOS after HSCT.
Methods: After diagnosis of BOS, 61 patients were treated with budesonide/formoterol, montelukast and
n-acetylcysteine for 3 months. Pulmonary function test and COPD assessment test (CAT) were performed
before and after the combination therapy. Therapeutic response was evaluated by changes in forced
expiratory volume in 1 s (FEV1) or CAT score.
Results: After 3 months of combination treatment, mean FEV1 increased by 220 mL (p < 0.001) and residual volume
decreased by 200 mL (p =0 .005). Median CAT score also significantly decreased from 15.5 to 11.0 (p = 0.001). The
overall response rate to combination therapy was 82 %. Comparing the no-response group and the response group,
the forced vital capacity (% predicted) decline between pre-HSCT and BOS diagnosis was significantly greater in the
response group (p = 0.036).
Conclusion: Combination treatment with budesonide/formoterol, montelukast and n-acetylcysteine significantly
improved lung function and respiratory symptoms in patients with BOS after allogeneic HSCT without serious side effects.
Keywords: Bronchiolitis obliterans syndrome, Inhaled corticosteroid, Long-acting β2-adrenergic agonist, Montelukast,
n-acetylcysteine
Background
Bronchiolitis obliterans syndrome (BOS) is a non-
infectious pulmonary complication of hematopoietic stem
cell transplantation (HSCT) that results in progressive
circumferential fibrosis of the small terminal airways,
manifesting as a fixed new-onset airflow obstruction
[1, 2]. Although BOS was previously regarded as rare,
recent data has reported that the overall prevalence
of BOS is 5.5 % in patients receiving allogeneic HSCT
and 14 % among patients who develop chronic graft
versus host disease (GVHD) [2]. In addition, patients
with BOS have poor prognosis, with an overall survival
rate of 44 % at 2 years and 13 % at 5 years [3].
The current treatment of post-HSCT BOS mainly
relies on systemic corticosteroids despite their poor
efficacy and significant side effects [4]. As a result, sev-
eral other immunosuppressive and immune-modulating
* Correspondence: jwlee@catholic.ac.kr
†Equal contributors
2Division of Hematology, Department of Internal Medicine, College of
Medicine, The Catholic University of Korea, Seoul, Korea
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. Respiratory Research  (2016) 17:63 
DOI 10.1186/s12931-016-0380-1
treatments have been investigated as treatment for
post-HSCT BOS [5–8]. Recently, potentially less toxic
treatments have emerged [4, 8, 9]. Norman et al.
retrospectively reviewed that combination therapy of
fluticasone, azithromycin and montelukast reduced
total corticosteroid exposure in eight HSCT patients
with BOS [8]. From prospective studies, montelukast
and low-dose macrolide also showed efficacy in BOS
after lung transplantation [10, 11]. Bergeron et al.
conducted a randomized controlled trial and showed
that inhaled budesonide/formoterol led to significant
improvement in FEV1 in 32 HSCT patients with mild to
severe BOS [9]. Despite studies with less toxic treatments
showing promising results, more prospective studies with
a large study population are required.
In this study, we investigated the impact of combin-
ation therapy with budesonide/formoterol, montelu-
kast and n-acetylcysteine in 61 patients with BOS
after HSCT. N-acetylcysteine was included based on
its potential therapeutic role and low toxicity [12, 13].
Methods
Patients
Post-HSCT patients with respiratory symptoms or pul-
monary function decline were referred to the pulmonol-
ogy department from the BMT Center in Seoul St. Mary’s
Hospital, Seoul, Korea. After clinical diagnosis of BOS,
one experienced pulmonologist (Rhee CK) treated all
patients according to the same protocol and follow-up
evaluation. After a retrospective chart review, patients
treated with budesonide/formoterol, montelukast and
n-acetylcysteine during the period between January
2011 and June 2015 were enrolled.
The inclusion criteria were 1) chronic GVHD in other
organs and positive diagnostic pulmonary function test
(PFT) using the modified NIH criteria [1, 2, 4] and 2)
treatment with budesonide/formoterol, montelukast and
n-acetylcysteine for at least 3 months. The exclusion
criteria were 1) other pulmonary or infectious diseases,
such as asthma, lung cancer, COPD, pneumonia or
tuberculosis destroyed lungs, and 2) a history of using
other inhalers. Approval was obtained from the institu-
tional review board of Seoul St. Mary’s Hospital
(KC15RISI0584). The requirement for informed consent
was waived by the ethical review board.
Definition of bronchiolitis obliterans syndrome (BOS)
The diagnostic criteria for BOS were as follows: (1) In
patients that underwent a lung biopsy, fibrogenic
deposition in the small airways or the bronchioles
satisfied the diagnostic criteria for BOS. (2) In patients
who did not undergo lung biopsy, chronic GVHD in
other organs, air trapping on high-resolution computed
tomography (HRCT) and positive diagnostic PFT of the
modified NIH criteria [1, 2, 4] were required: (i) forced
expiratory volume in 1 s (FEV1) of < 75 % of predicted or
decrease of the FEV1 by 10 % in comparison to the
pretransplant value, (ii) FEV1/forced vital capacity (FVC)
of < 70 % or residual volume (RV) of > 120 % predicted.
The reading of HRCT was performed by one radiology
specialist (Jung JI [14–16]). During the analysis of each
CT examination, the inspiratory images were reviewed
before the expiratory images. Air trapping on HRCT was
considered as present on the expiratory images when
lung regions failed to increase in attenuation and/or
failed to decrease in volume compared with the inspira-
tory images [17]. Patients who satisfied the diagnostic
criteria but had not developed an active infectious
disease were categorized as having BOS.
Combination therapy
After diagnosis of BOS, the patients enrolled in this
study were treated with a combination of budesonide/
formoterol, montelukast and n-acetylcysteine. Patients
received 160 μg of budesonide plus 4.5 μg of formoterol
fumarate in a dry powder inhaler (Symbicort Turbuhaler;
AstraZeneca, Mölndal, Sweden) twice daily, 10 mg monte-
lukast orally daily and 200 mg n-acetylcysteine orally three
times a day.
Pulmonary function test (PFT)
PFT was performed at pre-HSCT, BOS diagnosis and after
3 months of combination therapy. Patients underwent a
lung function assessment using a body box plethysmogra-
phy (SensorMedics Vmax series 22, VIASYS Healthcare,
Yorba Linda, CA) to measure flow rates, lung volumes
and diffusion capacity.
COPD assessment test (CAT) scoring
The CAT is a validated self-administered questionnaire
that measures health-related quality of life [18]. CAT
scores correlate with St. George’s Respiratory Question-
naire scores [18]. The Korean version of the CAT has also
been validated [19]. The CAT comprises eight symptoms:
cough, phlegm, chest tightness, breathlessness going up
hills/stairs, activity limitation at home, confidence leaving
home, sleep, and energy [20]. The score of each question-
naire ranges from 0 to 5. CAT scoring was evaluated at
BOS diagnosis and after 3 months of treatment.
Defining the group responding to the combination therapy
After 3 months of combination therapy and following
clinical evaluation with PFT and CAT scoring, patients
were categorized into two groups according to therapeutic
response: above or below the minimum clinically import-
ant difference (MCID, the threshold distinguishing
between a small meaningless change and a small but
meaningful change) [21]. The established MCID for FEV1
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and CAT are 100 mL [22] and 2 points, respectively [23].
Therapeutic response group was defined as an increase of
FEV1 more than 100 mL or a decrease in the CAT score
of greater than 2 points.
Statistical analysis
Means and standard deviation were computed for
normally distributed continuous variables, whereas
medians and interquartile ranges (25th–75th) were used
for non-normally distributed continuous data. Categor-
ical data are described as numbers and percentages (%).
For comparison of PFT and CAT scores between BOS
diagnosis and after combination treatment for 3 months,
the paired t-test and the Wilcoxon signed-rank test were
performed, respectively. For comparison of continuous
variables between the therapeutic response group and
the no-response group, student’s t-test was performed for
normally distributed data and the Mann–Whitney U test
was used for non-normally distributed data. Categorical
variables were compared using the Chi-square and the
Fisher’s exact tests as appropriate. Missing values were
excluded from the analysis. Statistical analysis was
performed using SPSS version 18.0 (SPSS Inc., Chicago,
IL, USA). A value of p < 0.05 was considered statistically
significant.
Results
Baseline characteristics of all patients with BOS
Of the 165 patients who were diagnosed with BOS in
the pulmonology department from January 2011 to June
2015, 61 patients met the inclusion criteria. Patients’
basic characteristics are shown in Table 1. All patients
received combination therapy (budesonide/formoterol,
montelukast and n-acetylcysteine) for at least 3 months
without serious side effects. Oral candidiasis was re-
ported in four patients and nausea was observed in one
patient; these minor problems were well controlled with
appropriate support. Patients showed good compliance
to the combination treatment. Among the 61 treated pa-
tients, four had a problem with the proper inhaler device
use and one had a problem with taking the oral drugs
regularly. In our center, all BOS patients are managed by
one experienced specialist (Rhee CK). Proper education
were provided by special pharmacist and inhaler
technique was checked in each visit. Even though, four
patients had a problem with the appropriate inhaler
technique. Reeducation was performed to improve
compliance.
Change in pulmonary function after 3 months
combination therapy
Table 2 and Fig. 1 show pulmonary function at pre-HSCT,
BOS diagnosis and 3 months after treatment. After treat-
ment, FEV1 (L) and FVC (L) increased significantly
Table 1 Basic characteristics of total patients with Bronchiolitis
Obliterans Syndrome (BOS)
Characteristics (N = 61)
Recipient sex, male 33/61 (54.1 %)
Recipient age 46.5 ± 12.3
Donor sex, male 32/59 (54.2 %)
Donor agea 37.1 ± 11.7
Hematologic malignancy
AML 17 (27.9 %)
ALL 20 (32.8 %)
CML 1 (1.6 %)
NHL 2 (3.3 %)
MDS 21 (34.4 %)
Donor type
Unrelated 28 (45.9 %)
Sibling 25 (41.0 %)
FMT 8 (13.1 %)
HLA
full-match 43 (70.5 %)
mismatch 18 (29.5 %)
Stem cell source
PB 51 (83.6 %)
BM 8 (13.1 %)
Cord 2 (3.3 %)
Time from HSCT to BOS diagnosis, days 434.0 (275.0–835.5)
Acute GVHD 39 (63.9 %)
Chronic GVHD (except lung) 61 (100.0 %)
Skin 31 (50.8 %)
Oral 42 (68.9 %)
Eyes 36 (59.0 %)
Liver 10 (16.4 %)
Joint 3 (4.9 %)
Maximal score of chronic GVHD (except lung)b 1 (1–2)
Systemic steroid use 33 (54.1 %)
Steroid dose, mg (equivalent dose of prednisolone) 2.5 (0.0–15.0)
Tacrolimus 18 (29.5 %)
Cyclosporin 9 (14.8 %)
Mycophenolate mofetil 18 (29.5 %)
aAge of two donors were missed because of cord blood transplantation
(N = 59). bEach organ was scored as 0, 1, 2 or 3 based on the degree of
functional impairment. Data represent the mean ± SD, median (IQR) or n
(%). BOS bronchiolitis obliterans syndrome, AML acute myeloid leukemia,
ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia,
NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, FMT
familial-mismatched/haploidentical transplantation, HLA human leukocyte
antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem
cell transplantation, GVHD graft-versus-host disease
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compared to measurements at BOS diagnosis (0.22 ±
0.43 L and 0.23 ± 0.43 L, respectively; p < 0.001, for both).
Percentage of FEV1 and FVC also increased significantly.
Although statistically borderline, FEV1/FVC increased
with combination treatment (63.80 ± 15.34 at BOS diagno-
sis and 65.83 ± 16.25 after 3 months treatment; p = 0.054).
RV (L) and RV/TLC (%) significantly decreased with the
therapy (p = 0.005 and p < 0.001, respectively). The ratio
of RV/TLC to predicted value also significantly decreased
(p < 0.001). There was no significant change in TLC with
combination treatment. DLCO improved with combin-
ation therapy (p = 0.027).
Table 2 Changes of pulmonary function test after 3 months combination therapy
Clinical variable Pre-HSCTa BOS diagnosis 3 months treatment Change of lung function between
3 months treatment and BOS diagnosis
P-value (BOS diagnosis vs
3 months treatment)
FVC (L) 3.70 ± 0.86 2.95 ± 0.81 3.18 ± 0.81 0.23 ± 0.43 < .001
FVC (% predicted) 94.14 ± 12.71 73.02 ± 13.23 78.41 ± 13.87 5.39 ± 10.11 < .001
FEV1 (L) 2.94 ± 0.69 1.85 ± 0.57 2.07 ± 0.68 0.22 ± 0.43 < .001
FEV1 (% predicted) 96.00 ± 13.68 56.68 ± 15.48 63.03 ± 19.31 6.36 ± 12.72 < .001
FEV1/FVC (%) 79.86 ± 7.14 63.80 ± 15.34 65.83 ± 16.25 2.04 ± 8.09 .054
RV(L) 1.37 ± 0.38 2.04 ± 0.70 1.84 ± 0.68 −0.20 ± 0.47 .005
RV (% predicted) 79.23 ± 17.64 114.24 ± 36.48 100.41 ± 34.06 −12.90 ± 25.71 .005
TLC (L) 5.11 ± 1.06 5.03 ± 1.13 5.07 ± 1.07 0.04 ± 0.46 .510
TLC (% predicted) 92.93 ± 10.80 89.04 ± 12.31 88.82 ± 11.09 0.45 ± 7.65 .675
RV/TLC (%) 27.02 ± 5.65 40.35 ± 9.79 36.12 ± 10.28 −4.35 ± 7.34 < .001
RV/TLC (% predicted) 83.50 ± 15.77 125.71 ± 33.70 111.22 ± 33.98 −14.06 ± 24.22 < .001
DLCO (% predicted) 62.05 ± 15.51 62.39 ± 17.46 66.32 ± 18.38 4.41 ± 13.80 .027
aFour missing values in Pre-HSCT (N = 57). Data represent the mean ± SD. P-values shown in bold are significant at the 0.05 level. HSCT hematopoietic stem cell
transplantation, BOS bronchiolitis obliterans syndrome, FVC forced vital capacity, FEV1 forced expiratory volume in 1s, RV residual volume, TLC total lung capacity,
DLCO carbon monoxide diffusion in the lung
Fig. 1 Changes in pulmonary function after 3 months combination therapy. a After 3 months of combination treatment, FEV1 (% predicted) and
FVC (% predicted) increased significantly. Percentage of FEV1 and FVC also increased after combination therapy, but the results were not significant.
b RV (% predicted) and RV/TLC (% predicted) significantly decreased with combination therapy, whereas TLC (% predicted) did not change. c DLCO
significantly improved with combination therapy. *p < 0.05, **p < 0.01 compared with measurements at BOS diagnosis
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Change in CAT score after combination therapy
Fifty-two patients completed the CAT questionnaire at
the time of BOS diagnosis and after finishing 3 months
combination treatment (Table 3). After treatment, the
total CAT score decreased significantly (p = 0.001). Total
CAT scores at BOS diagnosis and after 3 months treat-
ment were 15.5 (IQR, 9.25 to 19.0) and 11.0 (IQR, 6.0 to
15.75), respectively. When comparing in detail, scores
for all individual questions decreased significantly,
except for question 2 (phlegm) and question 5 (activities
at home).
Therapeutic response and association with pulmonary
function change
Therapeutic response was evaluated by considering the
improvement of FEV1 or CAT score. Sixty-two percent
of patients had an increase in FEV1 of greater than
100 mL (Fig. 2). Using the CAT score, 62 % of patients
also showed a decrease of greater than 2 points. When
the FEV1 and CAT score were combined, the overall
response rate to combination therapy was 82 %. Com-
paring the no-response group and the response group,
there was no significant difference in baseline character-
istics or total CAT score at enrollment (Table 4). PFT at
BOS diagnosis also did not significantly differ according
to therapeutic response (Table 5). However, the decline
of FVC (% predicted) between the time of pre-HSCT
and BOS diagnosis was significantly greater in the re-
sponse group (p = 0.036).
Discussion
In this study, the therapeutic effect of budesonide/formo-
terol, montelukast and n-acetylcysteine was analyzed in
patients with BOS after allogeneic HSCT. After 3 months
of treatment, the lung function and respiratory symptoms
were significantly improved without significant adverse
effects. In addition, the overall response rate to combin-
ation therapy was 82 %.
For patients with BOS, the main treatment at present
is immunosuppressive agents such as corticosteroids,
calcineurin inhibitors, sirolimus, azathioprine, and
antithymocyte globulin (ATG) [3, 4]. However, less than
20 % of patients improve and 65 % of patients with BOS
will die within 3 years of diagnosis regardless of the
therapies administered [1, 24, 25]. Side effects from the
immunosuppressive agents are also a problem [4, 24].
Recently, studies with potentially less toxic treatments
such as low-dose macrolide antibiotics, leukotriene
receptor antagonists, and combinations of inhaled
bronchodilators and glucocorticoids have been shown to
lead to PFT stabilization or improvement [9–11, 26].
Moreover, a combination of these alternative treatments
is under investigation [8, 27, 28]. The rationale for bude-
sonide/formoterol, montelukast and n-acetylcysteine
combination therapy, used in our study, is also based on
previous reports of each drug.
Inhaled corticosteroids (ICS) were suggested to have
therapeutic efficacy and reduce the side effects of sys-
temic treatment in patients with bronchiolitis obliterans
(BO) [29]. From a randomized controlled trial, Bergeron
et al. reported an improvement in FEV1 with budeso-
nide/formoterol combination therapy in patients with
BO [7]. The effect of montelukast, a leukotriene receptor
antagonist (LTRA), was investigated in other studies.
Cysteinyl leukotrienes are known to have important
bronchoconstrictive and proinflammatory effects [30].
From prospective studies, Verleden et al. reported
adding montelukast as a treatment in patients with BOS
[10] and Or et al. showed that montelukast had efficacy
in chronic GVHD when added to standard immunosup-
pressive regimens [31]. Moreover, adding montelukast is
a cheap and relatively safe option. Combination of inhaled
fluticasone, azithromycin and montelukast was also
suggested to halt pulmonary decline and permit reduc-
tions in systemic steroid exposure [28]. N-acetylcysteine
was suggested to improve clinical conditions and spiro-
metric findings in BOS from randomized clinical trial
[13]. N-acetylcysteine is categorized as a mucolytic, but
also has antioxidant effects [32]. Reactive oxygen species
have also been suggested to play an important role in
functional and structural changes in BOS [33]. In an in
vitro study using human airway smooth muscle cells,
n-acetylcysteine inhibited interleukin (IL)-17 induced IL-8
production, which is highly correlated with BO [33–35].
Although BOS had been thought as irreversible lung
disease and most studies focused on disease stability ra-
ther than an improvement in lung function [10, 28, 29],
our results showed a significant improvement in lung
function and symptoms. Beneficial effects shown in our
combination therapy may depend on bronchodilation,
Table 3 Changes of COPD assessment test (CAT) score after
therapy (N = 52)
Clinical variable BOS diagnosis 3 months
treatment
P-value
Q1. Cough 1.5 (0–2) 1 (0–2) .022
Q2. Phlegm 1 (0–2) 1 (0–2) .983
Q3. Chest tightness 2 (1–3) 1 (0–2) .000
Q4. Breathlessness going up
hills/stairs
3 (2–4) 3 (1.25-3) .002
Q5. Activity limitation at home 1 (0–2) 0 (0–1) .054
Q6. Confidence leaving home 1 (0–3) 1 (0–2) .013
Q7. Sleep 2 (1–3) 1 (0–2.75) .004
Q8. Energy 2 (2–3) 2 (1–3) .035
Total sum of the eight items 15.5 (9.25–19.0) 11.0 (6.0–15.75) .001
Data represent the median (IQR). P-values shown in bold are significant at the
0.05 level
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anti-inflammatory and anti-fibrotic effects. The precise
mechanism, interaction and beneficial potency of each
drug requires further investigation. Barisone et al.
suggested that the airway smooth muscle tone plays a
significant role in BOS after HSCT and reversibility [36].
In addition, beneficial effects with FEV1 improvement
were reported with budesonide/formoterol, azithromycin
and N-acetylcysteine treatment, respectively [9, 11, 13].
Previous reports in patients with other obstructive lung
diseases can also be used as a reference. The combin-
ation of ICS and long-acting bronchodilators (LABA)
instead of ICS alone has been suggested to provide
synergistic effects on bronchodilation and anti-
inflammation [37, 38]. The ICS/LABA combination is
also used in severe COPD to reduce exacerbations and
improve health status and FEV1 compared to mono-
therapy [39]. Keith et al. reported the effectiveness of
montelukast add-on therapy for managing asthma and
allergic rhinitis symptoms [40]. From a meta-analysis,
LTRAs as a monotherapy improved asthma control com-
pared with placebo [41]. The addition of n-acetylcysteine
in COPD further improved respiratory symptoms,
whereas there was no significant change in FEV1 [42, 43].
Long-term use of n-acetylcysteine has shown benefits in
the prevention of COPD exacerbation [44].
As a result, we suggest that the PFT improvement
mainly originated from ICS/LABA inhalation. The
addition of montelukast and n-acetylcysteine may
contribute to improvements in respiratory symptoms.
This suggestion coincides with results from Bergeron et
al. [9], who used budesonide/formoterol for BOS after
HSCT and observed a significant improvement in FEV1,
though no changes were seen in respiratory symptoms.
However, this suggestion should be proved by well-
designed clinical trials in the future.
In this study, the decline in FVC between pre-HSCT
and BOS diagnosis was significantly greater in the
response group compared to the non-response group.
However, this finding does not imply that the combin-
ation regimen in our study is effective only in advanced
patients. A good response in patients with a significantly
declined FVC may result from low lung function.
Further studies are required to identify determinants of
good response to the combination therapy. In addition,
PFT before transplantation is important as a reference
for later PFT measurements and helps early diagnosis
[45]. Early diagnosis and treatment of BO may improve
response over therapy initiated after structural, fibrotic
changes have occurred.
We are aware of limitations in this study. Although we
employed a consistent treatment plan and regular
follow-up by an expert pulmonologist, this study was
not a randomized controlled study and the effect of the
combination therapy was not compared with a placebo
group. Second, the beneficial effects of our combination
therapy in lung function and respiratory symptoms re-
quire further investigation assessing each drug and their
interactions. It is unclear that the improved lung func-
tion or symptoms were from the budesonide/formoterol
inhalation or the combination treatment. Third, further
studies are required to assess long-term outcome and
survival benefits. Fourth, analyzing the effect of the
combination treatment considering the changes of other
systemic immunosuppressive medications were not done
in this study. Finally, patients in our study received edu-
cation about the appropriate use of budesonide/
Fig. 2 Rate of therapeutic response to combination therapy evaluated by improvement of FEV1 or CAT score. Sixty-two percent of patients showed an
increase in FEV1 greater than 100 mL and the same proportion had a decrease in CAT score of greater than 2 points. When the results of FEV1 and
CAT score were combined, the overall response rate of the combination therapy was 82 %
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formoterol Turbuhaler and showed good compliance.
However, more precise measurements using the inhaler
and studies with other inhalers and devices are also
required.
Conclusion
The combination of budesonide/formoterol, montelu-
kast and n-acetylcysteine significantly improved lung
function and respiratory symptoms in patients with BOS
after allogeneic HSCT. Furthermore, combination ther-
apy showed better therapeutic response in patients with
BOS who showed prominent lung function decreases
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FVC (% predicted) 72.27 ± 15.42 73.19 ± 12.87 .838
FEV1 (% predicted) 56.46 ± 16.05 56.73 ± 15.52 .959
FEV1/FVC (%) 63.64 ± 10.54 63.83 ± 16.29 .970
RV (% predicted) 103.50 ± 39.10 116.68 ± 35.88 .307
TLC (% predicted) 82.30 ± 11.58 90.57 ± 12.07 .054
RV/TLC (%) 37.80 ± 10.76 40.93 ± 9.59 .366
DLCO (% predicted) 58.40 ± 21.81 63.30 ± 16.49 .429
Pre-HSCT – BOS diagnosisa
Δ FVC (% predicted) 12.45 ± 13.28 23.59 ± 15.88 .036
Δ FEV1 (% predicted) 30.81 ± 18.16 40.61 ± 18.89 .126
Δ FEV1/FVC (%) 18.18 ± 12.78 14.46 ± 15.63 .467
Δ RV (% predicted) −20.20 ± 32.45 −36.63 ± 35.90 .194
Δ TLC (% predicted) 3.90 ± 13.85 3.63 ± 11.25 .948
Δ RV/TLC (%) −9.90 ± 7.69 −14.08 ± 10.17 .232
Δ DLCO (% predicted) −1.00 ± 20.75 −0.51 ± 16.73 .937
aFour missing values in Pre-HSCT (N = 57). Data represent the mean ± SD.
P-values shown in bold are significant at the 0.05 level. HSCT hematopoietic
stem cell transplantation, BOS bronchiolitis obliterans syndrome, FVC forced
vital capacity, FEV1 forced expiratory volume in 1s, RV residual volume,
TLC total lung capacity, DLCO carbon monoxide diffusion in the lung







Recipient sex, male 8/11 25/50 .171
Recipient age 43.6 ± 15.4 47.1 ± 11.7 .389
Donor sex, male 5/11 27/48 .517

























Acute GVHD 8/11 31/50 .731
Chronic GVHD (except lung)
Skin 6/11 25/50 0.785
Oral 7/11 35/50 0.726
Eyes 9/11 27/50 0.106
Liver 2/11 8/50 1.000
Joint 0/11 3/50 1.000
Maximal score of chronic
GVHD (except lung)a
1 (1–2) 1 (1–2) 0.227
Systemic steroid 8/11 25/50 .171
Steroid dose, mg (equivalent
dose of prednisolone)
12.5 (4.4–16.3) 2.5 (0.0–15.0) .151
Tacrolimus 3/11 15/50 1.000
Cyclosporin 1/11 8/50 .683
Mycophenolate mofetil 5/11 13/50 .275
total CAT score, enroll 10.5 (6.8–16.0) 16.0 (10.0–20.0) .083
aEach organ was scored as 0, 1, 2 or 3 based on the degree of functional
impairment. Data represent the mean ± SD, median (IQR) or n. AML acute
myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic
myelogenous leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic
syndrome,
FMT familial-mismatched/haploidentical transplantation, HLA human leukocyte
antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem cell
transplantation, BOS bronchiolitis obliterans syndrome, GVHD graft-versus-host
disease, CAT COPD assessment test
Kim et al. Respiratory Research  (2016) 17:63 Page 7 of 9
Competing interests
C-K Rhee has received honoraria for lectures and/or consulting from MSD
Korea, AstraZeneca Korea, Novartis Korea, Takeda Korea, GlaxoSmithKline
Korea, Mundipharma Korea, Sandoz Korea, and Boehringer-Ingelheim Korea.
The other authors have no financial conflicts of interest. The other authors
declare that they have have no competing interests. The English in this
document has been checked by at least two professional editors, both native
speakers of English. For a certificate, please see: http://www.textcheck.com/
certificate/RfypqW.
Author details
1Division of Pulmonary, Allergy and Critical Care Medicine, Department of
Internal Medicine, College of Medicine, The Catholic University of Korea,
Seoul, Korea. 2Division of Hematology, Department of Internal Medicine,
College of Medicine, The Catholic University of Korea, Seoul, Korea.
Received: 4 December 2015 Accepted: 18 May 2016
References
1. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans
after allogeneic hematopoietic stem cell transplantation. JAMA.
2009;302:306–14.
2. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology
after allogeneic hematopoietic cell transplantation. Biol Blood Marrow
Transplant. 2011;17:1072–8.
3. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans
syndrome after allogeneic hematopoietic stem cell transplantation-an
increasingly recognized manifestation of chronic graft-versus-host disease.
Biol Blood Marrow Transplant. 2010;16:S106–114.
4. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J
Med. 2014;370:1820–8.
5. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS,
Joo YD, et al. Weekly rituximab followed by monthly rituximab treatment
for steroid-refractory chronic graft-versus-host disease: results from a
prospective, multicenter, phase II study. Haematologica. 2010;95:1935–42.
6. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human
soluble tumor necrosis factor receptor fusion protein as treatment for
steroid refractory graft-versus-host disease following allogeneic
hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45–52.
7. Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A, Esperou H, Ades L,
Gluckman E, Socie G, Tazi A. Combined inhaled steroids and bronchodilatators
in obstructive airway disease after allogeneic stem cell transplantation. Bone
Marrow Transplant. 2007;39:547–53.
8. Norman BC, Jacobsohn DA, Williams KM, Au BK, Au MA, Lee SJ, Moravec CK,
Chien JW. Fluticasone, azithromycin and montelukast therapy in reducing
corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic
hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant.
2011;46:1369–73.
9. Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault De Latour R,
Dominique S, de Revel T, Juvin K, Maillard N, et al. Budesonide/Formoterol
for bronchiolitis obliterans after hematopoietic stem cell transplantation.
Am J Respir Crit Care Med. 2015;191:1242–9.
10. Verleden GM, Verleden SE, Vos R, De Vleeschauwer SI, Dupont LJ, Van
Raemdonck DE, Vanaudenaerde BM. Montelukast for bronchiolitis obliterans
syndrome after lung transplantation: a pilot study. Transpl Int. 2011;24:651–6.
11. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-
term azithromycin for bronchiolitis obliterans syndrome after lung
transplantation. Transplantation. 2008;85:36–41.
12. Ghanei M, Shohrati M, Jafari M, Ghaderi S, Alaeddini F, Aslani J.
Nacetylcysteine improves the clinical conditions of mustard gas-exposed
patients with normal pulmonary function test. Basic Clin Pharmacol Toxicol.
2008; 103:428-32.
13. Shohrati M, Aslani J, Eshraghi M, Alaedini F, Ghanei M. Therapeutics effect of
N-acetyl cysteine on mustard gas exposed patients: evaluating clinical
aspect in patients with impaired pulmonary function test. Respir Med.
2008;102:443–8.
14. Jung JI, Jung WS, Hahn ST, Min CK, Kim CC, Park SH. Bronchiolitis obliterans
after allogenic bone marrow transplantation: HRCT findings. Korean J Radiol.
2004;5:107–13.
15. Choi MH, Jung JI, Chung WD, Kim YJ, Lee SE, Han DH, Ahn MI, Park SH. Acute
pulmonary complications in patients with hematologic malignancies.
Radiographics. 2014;34:1755–68.
16. Oh JK, Jung JI, Han DH, Ahn MI, Park SH, Cho BS, Min WS. Multidetector row
computed tomography quantification of bronchiolitis obliterans syndrome
after hematopoietic stem cell transplantation: a pilot study. J Thorac
Imaging. 2013;28:114–20.
17. Rhee CK, Ha JH, Yoon JH, Cho BS, Min WS, Yoon HK, Lee JW. Risk factor and
clinical outcome of bronchiolitis obliterans syndrome after allogeneic
hematopoietic stem cell transplantation. Yonsei Med J. 2016;57:365–72.
18. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a
systematic review. Eur Respir J. 2014;44:873–84.
19. Lee BY, Lee S, Lee JS, Song JW, Lee SD, Jang SH, Jung KS, Hwang YI, Oh YM.
Validity and reliability of CAT and dyspnea-12 in bronchiectasis and
tuberculous destroyed lung. Tuberc Respir Dis (Seoul). 2012;72:467–74.
20. Lee YS, Park S, Oh YM, Lee SD, Park SW, Kim YS, In KH, Jung BH, Lee KH,
Ra SW, et al. Chronic obstructive pulmonary disease assessment test can
predict depression: a prospective multi-center study. J Korean Med Sci.
2013;28:1048–54.
21. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining
the minimal clinically important difference. Control Clin Trials. 1989;10:407–15.
22. Donohue JF. Minimal clinically important differences in COPD lung function.
Copd. 2005;2:111–24.
23. Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden
BM, Polkey MI, Man WD. Minimum clinically important difference for the
COPD assessment test: a prospective analysis. Lancet Respir Med.
2014;2:195–203.
24. Chan CK, Hyland RH, Hutcheon MA, Minden MD, Alexander MA,
Kossakowska AE, Urbanski SJ, Fyles GM, Fraser IM, Curtis JE, et al.
Small-airways disease in recipients of allogeneic bone marrow transplants.
An analysis of 11 cases and a review of the literature. Medicine (Baltimore).
1987;66:327–40.
25. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, Clark JG.
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell
transplantation. Am J Respir Crit Care Med. 2003;168:208–14.
26. Benden C, Boehler A. Long-term clarithromycin therapy in the management
of lung transplant recipients. Transplantation. 2009;87:1538–40.
27. Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T,
Robin M, Ribaud P, Socie G, Tazi A. Bronchiolitis obliterans syndrome after
allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow
Transplant. 2013;48:819–24.
28. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J,
Johnston L, Mayer S, et al. Fluticasone, azithromycin, and Montelukast
treatment for New-onset bronchiolitis obliterans syndrome after
hematopoietic cell transplantation. Biol Blood Marrow Transplant.
2015;22(4):710–6.
29. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, Safdar A,
Broglio KR, Adachi R, Dickey BF. Inhaled corticosteroids stabilize constrictive
bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow
Transplant. 2008;41:63–7.
30. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol.
2002;64:1549–57.
31. Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M, Sacks Z, Shapira MY.
Sparing effect by montelukast treatment for chronic graft versus host disease: a
pilot study. Transplantation. 2007;83:577–81.
32. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as
apparently widely used messengers in the activation of the NF-kappa B
transcription factor and HIV-1. EMBO J. 1991;10:2247–58.
33. Wuyts WA, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, Demedts
MG, Verleden GM. N-acetylcysteine inhibits interleukin-17-induced
interleukin-8 production from human airway smooth muscle cells: a
possible role for anti-oxidative treatment in chronic lung rejection?
J Heart Lung Transplant. 2004;23:122–7.
34. Elssner A, Jaumann F, Dobmann S, Behr J, Schwaiblmair M, Reichenspurner
H, Furst H, Briegel J, Vogelmeier C. Elevated levels of interleukin-8 and
transforming growth factor-beta in bronchoalveolar lavage fluid from
patients with bronchiolitis obliterans syndrome: proinflammatory role of
bronchial epithelial cells. Munich Lung Transplant Group. Transplant. 2000;
70:362–7.
35. DiGiovine B, Lynch 3rd JP, Martinez FJ, Flint A, Whyte RI, Iannettoni MD,
Arenberg DA, Burdick MD, Glass MC, Wilke CA, et al. Bronchoalveolar lavage
Kim et al. Respiratory Research  (2016) 17:63 Page 8 of 9
neutrophilia is associated with obliterative bronchiolitis after lung
transplantation: role of IL-8. J Immunol. 1996;157:4194–202.
36. Barisione G, Bacigalupo A, Crimi E, Brusasco V. Acute bronchodilator
responsiveness in bronchiolitis obliterans syndrome following
hematopoietic stem cell transplantation. Chest. 2011;139:633–9.
37. Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment:
combination therapy with inhaled corticosteroids and long-acting beta 2-
agonists. Curr Pharm Des. 2006;12:3261–79.
38. Remington TL, Digiovine B. Long-acting beta-agonists: anti-inflammatory
properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med.
2005;11:74–8.
39. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC,
Vestbo J. Salmeterol and fluticasone propionate and survival in chronic
obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.
40. Keith PK, Koch C, Djandji M, Bouchard J, Psaradellis E, Sampalis JS,
Schellenberg RR, McIvor RA. Montelukast as add-on therapy with inhaled
corticosteroids alone or inhaled corticosteroids and long-acting beta-2-
agonists in the management of patients diagnosed with asthma and
concurrent allergic rhinitis (the RADAR trial). Can Respir J. 2009;16(A):17a–31a.
41. Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM.
Leukotriene-receptor antagonists versus placebo in the treatment of asthma
in adults and adolescents: a systematic review and meta-analysis. Ann
Intern Med. 2015;163(10):756–67.
42. Stiksa G, Nemcek K, Melin S. Effects of inhaled N-acetylcysteine in
combination with terbutaline. Eur J Respir Dis. 1984;65:278–82.
43. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van
Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M,
De Backer W, et al. Effects of N-acetylcysteine on outcomes in chronic
obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility
Study, BRONCUS): a randomised placebo-controlled trial. Lancet.
2005;365:1552–60.
44. Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X,
Raiteri L, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of
chronic obstructive pulmonary disease (PANTHEON): a randomised, double-
blind placebo-controlled trial. Lancet Respir Med. 2014;2:187–94.
45. Chien JW, Madtes DK, Clark JG. Pulmonary function testing prior to
hematopoietic stem cell transplantation. Bone Marrow Transplant.
2005;35:429–35.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kim et al. Respiratory Research  (2016) 17:63 Page 9 of 9
